z-logo
Premium
Quantification of glypican 3, β‐catenin and claudin‐1 protein expression in hepatoblastoma and paediatric hepatocellular carcinoma by colour deconvolution
Author(s) -
Zhou Shengmei,
Parham David M,
Yung Evan,
Pattengale Paul,
Wang Larry
Publication year - 2015
Publication title -
histopathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.626
H-Index - 124
eISSN - 1365-2559
pISSN - 0309-0167
DOI - 10.1111/his.12730
Subject(s) - glypican 3 , hepatoblastoma , claudin , immunohistochemistry , immunostaining , hepatocellular carcinoma , pathology , hccs , cancer research , biology , medicine , tight junction , microbiology and biotechnology
Aims To identify an immunohistochemical panel for paediatric malignant epithelial liver tumours. Methods and results Forty‐five hepatoblastomas ( HB s), 13 paediatric hepatocellular carcinomas ( HCC s) and two hepatocellular malignant neoplasms not otherwise specified ( NOS ) were chosen for immunohistochemical staining of glypican 3 ( GPC 3), β‐catenin, claudin‐1, delta‐like protein ( DLK ), and forkhead box protein G1 ( FOXG 1). Immunostaining was quantitatively analysed with NIH imagej software coupled with colour deconvolution. Different subtypes of HB and HCC showed distinct staining patterns of  GPC 3, β‐catenin, and claudin‐1. Moreover, GPC 3, β‐catenin and claudin‐1 all showed higher expression in classic HCC and embryonal HB than in fetal HB ; GPC 3 showed complete negativity in small‐cell undifferentiated ( SCU ) HB and fibrolamellar HCC ( FLC ); β‐catenin showed the strongest expression in SCU HB but the weakest expression in FLC . A panel of these three immunomarkers was useful for the diagnosis of hepatocellular malignant neoplasms NOS . The expression of DLK and FOXG 1 was inconstant among fetal and embryonal HB and classic HCC . Conclusions A panel of GPC 3, β‐catenin and claudin‐1 is helpful for differentiating HB subtypes and distinguishing HB from HCC .

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here